Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.

Zhang Q, Wang HY, Liu X, Nunez-Cruz S, Jillab M, Melnikov O, Nath K, Glickson J, Wasik MA.

J Immunol. 2019 Oct 15;203(8):2043-2048. doi: 10.4049/jimmunol.1801327. Epub 2019 Sep 18.

PMID:
31534006
2.

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.

JCI Insight. 2019 Feb 21;4(4). pii: 127684. doi: 10.1172/jci.insight.127684. eCollection 2019 Feb 21. No abstract available.

3.

Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells.

Ghassemi S, Nunez-Cruz S, O'Connor RS, Fraietta JA, Patel PR, Scholler J, Barrett DM, Lundh SM, Davis MM, Bedoya F, Zhang C, Leferovich J, Lacey SF, Levine BL, Grupp SA, June CH, Melenhorst JJ, Milone MC.

Cancer Immunol Res. 2018 Sep;6(9):1100-1109. doi: 10.1158/2326-6066.CIR-17-0405. Epub 2018 Jul 20.

4.

Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma.

Bu DX, Singh R, Choi EE, Ruella M, Nunez-Cruz S, Mansfield KG, Bennett P, Barton N, Wu Q, Zhang J, Wang Y, Wei L, Cogan S, Ezell T, Joshi S, Latimer KJ, Granda B, Tschantz WR, Young RM, Huet HA, Richardson CJ, Milone MC.

Oncotarget. 2018 May 25;9(40):25764-25780. doi: 10.18632/oncotarget.25359. eCollection 2018 May 25.

5.

The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations.

O'Connor RS, Guo L, Ghassemi S, Snyder NW, Worth AJ, Weng L, Kam Y, Philipson B, Trefely S, Nunez-Cruz S, Blair IA, June CH, Milone MC.

Sci Rep. 2018 Apr 19;8(1):6289. doi: 10.1038/s41598-018-24676-6.

6.

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.

JCI Insight. 2018 Apr 19;3(8). pii: 120505. doi: 10.1172/jci.insight.120505. eCollection 2018 Apr 19. Erratum in: JCI Insight. 2019 Feb 21;4(4):.

7.

Cytokines increase engraftment of human acute myeloid leukemia cells in immunocompromised mice but not engraftment of human myelodysplastic syndrome cells.

Krevvata M, Shan X, Zhou C, Dos Santos C, Habineza Ndikuyeze G, Secreto A, Glover J, Trotman W, Brake-Silla G, Nunez-Cruz S, Wertheim G, Ra HJ, Griffiths E, Papachristou C, Danet-Desnoyers G, Carroll M.

Haematologica. 2018 Jun;103(6):959-971. doi: 10.3324/haematol.2017.183202. Epub 2018 Mar 15.

8.

High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.

Richman SA, Nunez-Cruz S, Moghimi B, Li LZ, Gershenson ZT, Mourelatos Z, Barrett DM, Grupp SA, Milone MC.

Cancer Immunol Res. 2018 Jan;6(1):36-46. doi: 10.1158/2326-6066.CIR-17-0211. Epub 2017 Nov 27.

9.

Improving T Cell Expansion with a Soft Touch.

Lambert LH, Goebrecht GK, De Leo SE, O'Connor RS, Nunez-Cruz S, Li TD, Yuan J, Milone MC, Kam LC.

Nano Lett. 2017 Feb 8;17(2):821-826. doi: 10.1021/acs.nanolett.6b04071. Epub 2017 Jan 30.

10.

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.

Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone M, Lacey SF, Mato A, Schuster SJ, Kalos M, June CH, Gill S, Wasik MA.

Clin Cancer Res. 2016 Jun 1;22(11):2684-96. doi: 10.1158/1078-0432.CCR-15-1527. Epub 2016 Jan 27.

11.

Immunocompetent mouse model of ovarian cancer for in vivo imaging.

Nunez-Cruz S, Scholler N.

Methods Mol Biol. 2013;1049:425-33. doi: 10.1007/978-1-62703-547-7_32.

PMID:
23913235
12.

Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization.

Nunez-Cruz S, Gimotty PA, Guerra MW, Connolly DC, Wu YQ, DeAngelis RA, Lambris JD, Coukos G, Scholler N.

Neoplasia. 2012 Nov;14(11):994-1004.

13.

An orthotopic model of serous ovarian cancer in immunocompetent mice for in vivo tumor imaging and monitoring of tumor immune responses.

Nunez-Cruz S, Connolly DC, Scholler N.

J Vis Exp. 2010 Nov 28;(45). pii: 2146. doi: 10.3791/2146.

14.

Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform.

Zhao A, Nunez-Cruz S, Li C, Coukos G, Siegel DL, Scholler N.

J Immunol Methods. 2011 Jan 5;363(2):221-32. doi: 10.1016/j.jim.2010.09.001. Epub 2010 Sep 15.

15.

Differential requirement for the SAP-Fyn interaction during NK T cell development and function.

Nunez-Cruz S, Yeo WC, Rothman J, Ojha P, Bassiri H, Juntilla M, Davidson D, Veillette A, Koretzky GA, Nichols KE.

J Immunol. 2008 Aug 15;181(4):2311-20.

16.

Dynamic recruitment of the adaptor protein LAT: LAT exists in two distinct intracellular pools and controls its own recruitment.

Bonello G, Blanchard N, Montoya MC, Aguado E, Langlet C, He HT, Nunez-Cruz S, Malissen M, Sanchez-Madrid F, Olive D, Hivroz C, Collette Y.

J Cell Sci. 2004 Mar 1;117(Pt 7):1009-16.

17.

LAT regulates gammadelta T cell homeostasis and differentiation.

Nuñez-Cruz S, Aguado E, Richelme S, Chetaille B, Mura AM, Richelme M, Pouyet L, Jouvin-Marche E, Xerri L, Malissen B, Malissen M.

Nat Immunol. 2003 Oct;4(10):999-1008. Epub 2003 Sep 14.

PMID:
12970761
18.

Induction of T helper type 2 immunity by a point mutation in the LAT adaptor.

Aguado E, Richelme S, Nuñez-Cruz S, Miazek A, Mura AM, Richelme M, Guo XJ, Sainty D, He HT, Malissen B, Malissen M.

Science. 2002 Jun 14;296(5575):2036-40.

Supplemental Content

Loading ...
Support Center